drugset / Trial / NCT00686504

Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066

NCT00686504

Phase 1 Completed 6 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The study is carried out in order to determine the relationship between AZD2066 exposure and mGluR5 receptor occupancy in the brain and to demonstrate that AZD2066 can displace \[11C\]AZ12713580 from mGluR5 binding-sites in the Central Nervous System

Timeline

Start
2008-04
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AZ12713580 Unknown Intravenous
Subject AZD2066 Small molecule Oral

Indications

No indication recorded.